CAR Clinical Trial
Official title:
CAR-T CD19/CD20 for Patients With Advanced CD19/CD20+ B Cell Line Recurrent or Refractory Hematological Malignancies
This is a clinical study of CD19 / CD20 CAR-T cell infusion in the treatment of relapsed or refractory hematological malignancies in CD19 / CD20 positive B cell lines. The aim of this study was to evaluate the efficacy and safety of autologous chimeric antigen receptor T cell infusion targeting CD19/CD20 in the treatment of relapsed or refractory CD19 / CD20 positive B cell line hematological malignancies.
CD19 and CD20 are two proteins expressed in normal B cells and various B cell-derived hematological malignancies, including non Hodgkin's lymphoma (NHL), acute lymphoblastic leukemia (all) and chronic lymphoblastic leukemia (CLL). CD19 and CD20 are restricted to the surface of B cells. They are not expressed in hematopoietic stem cells, nor in other tissue cells. They exist in all stages of B cell development and differentiation. They are not lost from the cell surface until B cells differentiate into plasma cells. Clinical studies have found that CD19 and CD20 are excellent targets for immunotherapy of B-cell malignancies.The purpose of this study was to observe the efficacy and safety of treatment for patients with relapsed or refractory CD19 / CD20 positive B cell line hematological malignancies. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05043571 -
CARTALL: Chimeric-Antigen Receptor (CAR) T-Cell Therapy for Relapsed/ Refractory T-Lineage Acute Lymphoblastic Leukaemia
|
Phase 1 | |
| Recruiting |
NCT04691713 -
CD276 CAR-T for Patients With Advanced CD276+ Solid Tumors
|
N/A | |
| Recruiting |
NCT05648019 -
CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory B-Lineage Leukaemia / Lymphoma - A Feasibility Protocol
|
Phase 2 | |
| Recruiting |
NCT04702841 -
CAR - γ δ T Cells in the Treatment of Relapsed and Refractory CD7 Positive T Cell-derived Malignant Tumors
|
Early Phase 1 | |
| Recruiting |
NCT03267173 -
Evaluate the Safety and Efficacy of CAR-T in the Treatment of Pancreatic Cancer.
|
Early Phase 1 | |
| Recruiting |
NCT05429905 -
Dual Anti-CD22/CD19 Chimeric Antigen Receptor-directed T Cells (CART2219.1) for Relapsed Refractory B-Lineage Leukaemia
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05017883 -
TAA05 Cell Injection in the Treatment of Recurrent / Refractory Acute Myeloid Leukemia
|
N/A | |
| Recruiting |
NCT03198546 -
GPC3-CAR-T Cells for Immunotherapy of Cancer With GPC3 Expression
|
Phase 1 | |
| Recruiting |
NCT04692948 -
TAA6 Cell Injection In The Treatment of Patients With Relapsed / Refractory Acute Myeloid Leukemia
|
N/A | |
| Recruiting |
NCT05679687 -
ThisCART19A Bridging to alloHSCT for R/R B-ALL
|
Phase 1 | |
| Recruiting |
NCT05691153 -
ThisCART19A for B-NHL Relapsed After Auto-CAR T
|
Phase 1 | |
| Recruiting |
NCT05038696 -
ALaCART-B: Acute Leukemia and Chimeric Antigen Receptor-T Cell Therapy for B-lymphoblastic Leukemia.
|
Phase 1 |